Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The latest evidence on the treatment of urgent heart problems ... devices to support adults with rapidly deteriorating or severe cardiogenic shock was feasible but did not improve clinical ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first six hours of ...

The istaroxime patent is entitled, “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGEN1C SHOCK AND CARDIOGENIC SHOCK”, is No. PCT/US2023/018998 and was assigned ...

Windtree Therapeutics has announced the results from the Phase 2b study of its lead drug candidate, istaroxime, in the treatment of cardiogenic shock due to heart failure. The data from the study ...

One week later the patient presented at the emergency department of a different hospital with cardiogenic shock. His systolic BP was 50 mmHg and electrocardiography showed widespread, nonspecific ...

Johnson & Johnson MedTech’s Abiomed announced that its compressible, expandable heart pump has cleared a pivotal trial, and ...

The researchers conducted a retrospective single-center cohort study by analyzing past data taken from 114 patients with cardiogenic shock. These patients received treatment with VA-ECMO or the ...